NRXP Earnings Date: Nov 13, 2026 (Estimated) — NRx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is NRXP's next earnings date?
NRx Pharmaceuticals, Inc. (NRXP) is expected to report earnings on Friday, November 13, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.21 on revenue of $1.2M.
How did NRXP do in its last earnings report?
In its most recent report on Aug 17, 2026 (Q2 2026), NRx Pharmaceuticals, Inc. posted EPS of -$0.44 versus the -$0.11 estimate, a miss of 266.7%. Revenue was $1.1M against a $1.3M estimate. The stock's 1-day post-earnings move was +4.9%.
How much does NRXP stock move after earnings?
NRXP beat EPS estimates in 3 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 9.0% (up or down) in the day after earnings.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | Q2 2026 | -0.11 | -0.44 | -266.67% | $1.1M | ❌ Miss | +4.89% | +8.87% | +3.98% |
| 2026-05-15 | Q1 2026 | -0.10 | -0.04 | +60.00% | $1.1M | ✅ Beat | -5.03% | -1.83% | +21.04% |
| 2026-03-23 | Q4 2025 | -0.08 | 0.20 | +350.00% | $983,000 | ✅ Beat | +20.34% | +18.08% | +67.80% |
| 2025-11-17 | Q3 2025 | -0.05 | -0.27 | -440.00% | $242,000 | ❌ Miss | -15.26% | -14.46% | -15.66% |
| 2025-08-18 | Q2 2025 | -0.23 | -0.98 | -326.09% | $0 | ❌ Miss | -4.50% | -8.65% | +3.11% |
| 2025-03-17 | Q4 2024 | — | -0.77 | — | $0 | — | -12.77% | -11.49% | -13.62% |
| 2024-11-14 | Q3 2024 | -0.69 | -0.15 | +78.26% | $0 | ✅ Beat | +2.59% | +6.03% | +3.45% |
| 2024-08-14 | Q2 2024 | -0.58 | -0.75 | -29.31% | $0 | ❌ Miss | -6.45% | +2.15% | -7.53% |
Showing last 8 quarters.